Base de dados : MEDLINE
Pesquisa : D03.633.100.127.075 [Categoria DeCS]
Referências encontradas : 7223 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 723 ir para página                         

  1 / 7223 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29424993
[Au] Autor:Martynova NA; Zakharenkov VV; Oleshchenko AM; Gorokhova LG
[Ti] Título:[Hygienic standardization of 2-formylphenoxyethane acid in the air of the working zone Hygiene of Children and Adolescents].
[So] Source:Gig Sanit;95(7):633-6, 2016.
[Is] ISSN:0016-9900
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The toxic properties of 2-formylphenoxyethane acid for hygienic standardization in the air of the working zone were studied. DL of the substance under the introduction into the stomach for male rats, male and female mice was 5354, 3698 and 4322 mg/kg. This compound refers to moderately hazardous substances. No significant differences in species and gender sensitivity of animals to the substance were found. This compound possesses a strong ability to the accumulation: C accounts of 2.9. It has a marked irritating effect to the mucous membranes of eyes and the moderate impact to the skin. It has a toxic effect on the liver, kidneys, central nervous system. The threshold of acute inhalation effect (Lim) equals to 120.3 mg/m. It has no irritating effect to the respiratory tract at Lim level. The tentative safe exposure level of 2-formylphenoxyethane acid in the air of working zone equals to 1 mg/m.
[Mh] Termos MeSH primário: Amiodarona/química
Indústria Farmacêutica/normas
[Mh] Termos MeSH secundário: Poluentes Ocupacionais do Ar/análise
Poluentes Ocupacionais do Ar/química
Animais
Antiarrítmicos/química
Modelos Animais de Doenças
Seres Humanos
Concentração Máxima Permitida
Doenças Profissionais/induzido quimicamente
Doenças Profissionais/prevenção & controle
Ratos
Testes de Toxicidade/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Air Pollutants, Occupational); 0 (Anti-Arrhythmia Agents); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  2 / 7223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29248575
[Au] Autor:Natale A; Boeckmans J; Desmae T; De Boe V; De Kock J; Vanhaecke T; Rogiers V; Rodrigues RM
[Ad] Endereço:Department of In Vitro Toxicology & Dermato-Cosmetology (IVTD), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium. Electronic address: alessandra.natale@vub.be.
[Ti] Título:Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone.
[So] Source:Toxicol Lett;284:184-194, 2018 Mar 01.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Phospholipidosis is a metabolic disorder characterized by intracellular accumulation of phospholipids. It can be caused by short-term or chronic exposure to cationic amphiphilic drugs (CADs). These compounds bind to phospholipids, leading to inhibition of their degradation and consequently to their accumulation in lysosomes. Drug-induced phospholipidosis (DIPL) is frequently at the basis of discontinuation of drug development and post-market drug withdrawal. Therefore, reliable human-relevant in vitro models must be developed to speed up the identification of compounds that are potential inducers of phospholipidosis. Here, hepatic cells derived from human skin (hSKP-HPC) were evaluated as an in vitro model for DIPL. These cells were exposed over time to amiodarone, a CAD known to induce phospholipidosis in humans. Transmission electron microscopy revealed the formation of the typical lamellar inclusions in the cell cytoplasm. Increase of phospholipids was already detected after 24 h exposure to amiodarone, whereas a significant increase of neutral lipid vesicles could be observed after 72 h. At the transcriptional level, the modulation of genes involved in DIPL was detected. These results provide a valuable indication of the applicability of hSKP-HPC for the quick assessment of drug-induced phospholipidosis in vitro, early in the drug development process.
[Mh] Termos MeSH primário: Avaliação Pré-Clínica de Medicamentos/métodos
Hepatócitos/efeitos dos fármacos
Lipidoses/induzido quimicamente
Fosfolipídeos/metabolismo
Pele/citologia
Células-Tronco/citologia
[Mh] Termos MeSH secundário: Amiodarona/toxicidade
Diferenciação Celular/efeitos dos fármacos
Células Cultivadas
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Citometria de Fluxo
Expressão Gênica/efeitos dos fármacos
Células Hep G2
Hepatócitos/ultraestrutura
Seres Humanos
Lipidoses/genética
Lisossomos/efeitos dos fármacos
Lisossomos/metabolismo
Masculino
Fosfolipídeos/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Phospholipids); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171218
[St] Status:MEDLINE


  3 / 7223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29187111
[Au] Autor:Webster G
[Ad] Endereço:1 Division of Cardiology, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
[Ti] Título:Aiming at a Blurry Target: Optimal Therapy for Postoperative JET.
[So] Source:World J Pediatr Congenit Heart Surg;8(6):691-693, 2017 11.
[Is] ISSN:2150-136X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Amiodarona
Taquicardia Ectópica de Junção
[Mh] Termos MeSH secundário: Antiarrítmicos
Cardiopatias Congênitas
Seres Humanos
Lactente
Complicações Pós-Operatórias
Período Pós-Operatório
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1177/2150135117738009


  4 / 7223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245320
[Au] Autor:Wei A; Peng J; Gu Z; Li J
[Ad] Endereço:aDepartment of Pharmacy, Tongji HospitalbDepartment of Endocrinology, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, WuhancDepartment of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
[Ti] Título:QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.
[So] Source:Medicine (Baltimore);96(49):e9071, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Drug-induced prolongation of the corrected QT interval (QTc) may lead to serious and potentially life-threatening ventricular tachyarrhythmia, such as torsades de pointes (Tdp), which is worthy of clinical attention. Here, we report 1 case of Tdp after a coadministration of fluoxetine and amiodarone. PATIENT CONCERNS: A 62-year-old Chinese male who placed with the implanted cardioverter-defibrillator (ICD) appeared the QTc prolongation and Tdp after the concurrent administration of fluoxetine and amiodarone. DIAGNOSES: Torsades de pointes (Tdp). INTERVENTIONS: The patient was treated with magnesium and potassium immediately. Her ICD-brady pacing mode was reprogrammed to 90 bpm. Meanwhile, both of fluoxetine and amiodarone were discontinued. OUTCOMES: The further episodes of Tdp were prevented. After a few days, the QTc gradually decreased without clinically significant arrhythmias. LESSONS: The present case demonstrates that a potential drug-drug interaction (DDI) may lead to a life-threatening drug adverse reaction (ADR) especially in special subjects. Therefore, clinicians should closely monitor the electrocardiogram (ECG) when QTc-prolonging agents are given to patients with cardiac abnormalities, and avoid combining 2 QTc-prolonging drugs.
[Mh] Termos MeSH primário: Amiodarona/efeitos adversos
Antiarrítmicos/efeitos adversos
Cardiomiopatia Dilatada/terapia
Desfibriladores Implantáveis
Interações Medicamentosas
Fluoxetina/efeitos adversos
Síndrome do QT Longo/induzido quimicamente
Inibidores da Captação de Serotonina/efeitos adversos
Torsades de Pointes/induzido quimicamente
[Mh] Termos MeSH secundário: Amiodarona/administração & dosagem
Antiarrítmicos/administração & dosagem
Eletrocardiografia
Fluoxetina/administração & dosagem
Seres Humanos
Masculino
Meia-Idade
Inibidores da Captação de Serotonina/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); 0 (Serotonin Uptake Inhibitors); 01K63SUP8D (Fluoxetine); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009071


  5 / 7223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453812
[Au] Autor:Spartalis M; Tzatzaki E; Schizas D; Spartalis E
[Ad] Endereço:Division of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.
[Ti] Título:eComment. Amiodarone-induced pulmonary toxicity in patients with atrial fibrillation undergoing lung resection.
[So] Source:Interact Cardiovasc Thorac Surg;24(5):788, 2017 05 01.
[Is] ISSN:1569-9285
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Amiodarona
Fibrilação Atrial
[Mh] Termos MeSH secundário: Antiarrítmicos
Seres Humanos
Pneumonectomia
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/icvts/ivx094


  6 / 7223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29220397
[Au] Autor:Bognar Z; Fekete K; Antus C; Hocsak E; Bognar R; Tapodi A; Boronkai A; Farkas N; Gallyas F; Sumegi B; Szanto A
[Ad] Endereço:Department of Biochemistry and Medical Chemistry, University of Pecs, Pecs, Hungary.
[Ti] Título:Desethylamiodarone-A metabolite of amiodarone-Induces apoptosis on T24 human bladder cancer cells via multiple pathways.
[So] Source:PLoS One;12(12):e0189470, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bladder cancer (BC) is a common malignancy of the urinary tract that has a higher frequency in men than in women. Cytostatic resistance and metastasis formation are significant risk factors in BC therapy; therefore, there is great interest in overcoming drug resistance and in initiating research for novel chemotherapeutic approaches. Here, we suggest that desethylamiodarone (DEA)-a metabolite of amiodarone-may have cytostatic potential. DEA activates the collapse of mitochondrial membrane potential (detected by JC-1 fluorescence), and induces cell death in T24 human transitional-cell bladder carcinoma cell line at physiologically achievable concentrations. DEA induces cell cycle arrest in the G0/G1 phase, which may contribute to the inhibition of cell proliferation, and shifts the Bax/Bcl-2 ratio to initiate apoptosis, induce AIF nuclear translocation, and activate PARP-1 cleavage and caspase-3 activation. The major cytoprotective kinases-ERK and Akt-are inhibited by DEA, which may contribute to its cell death-inducing effects. DEA also inhibits the expression of B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) and reduces colony formation of T24 bladder carcinoma cells, indicating its possible inhibitory effect on metastatic potential. These data show that DEA is a novel anti-cancer candidate of multiple cell death-inducing effects and metastatic potential. Our findings recommend further evaluation of its effects in clinical studies.
[Mh] Termos MeSH primário: Amiodarona/análogos & derivados
Apoptose/efeitos dos fármacos
Neoplasias da Bexiga Urinária/patologia
[Mh] Termos MeSH secundário: Amiodarona/farmacologia
Linhagem Celular Tumoral
Seres Humanos
Potencial da Membrana Mitocondrial/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
M31FU99E3Y (desethylamiodarone); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189470


  7 / 7223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453809
[Au] Autor:Kolokotroni SM; Toufektzian L; Harling L; Billè A
[Ad] Endereço:Department of Thoracic Surgery, Guy's Hospital, London, UK.
[Ti] Título:In patients undergoing lung resection is it safe to administer amiodarone either as prophylaxis or treatment of atrial fibrillation?
[So] Source:Interact Cardiovasc Thorac Surg;24(5):783-788, 2017 05 01.
[Is] ISSN:1569-9285
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether the administration of amiodarone is safe in patients undergoing lung resection either for prophylaxis or treatment of de novo postoperative atrial fibrillation (POAF). A total of 30 papers were identified, of which 13 represented the best evidence to answer the clinical question. The authors, journal, date, study type, country of publication, patient demographics, relevant outcomes and results were tabulated. Among the identified papers, there were 2 meta-analyses, 1 best evidence topic and 3 randomized studies, while the remainder were retrospective. When considering perioperative amiodarone for the prophylaxis of POAF, 3 randomized studies reported no significantly increased postoperative complications or amiodarone-related side effects. Mortality and length of hospital stay were similar in patients receiving amiodarone compared with either no amiodarone or other prophylactic antiarrhythmic medication. When considering amiodarone for the treatment of POAF, 1 study reported a significantly increased incidence of ARDS after anatomical lung resection (P < 0.001). Two case series reported that patients developing POAF after lung resection and managed with amiodarone also had either none or acceptable rates of side effects, with no serious respiratory complications. Two retrospective and 1 prospective observational study reported that amiodarone used either for the treatment of POAF, or for prophylaxis against it, had similar rates of postoperative respiratory complications, length of hospital stay and mortality, compared with either no treatment or treatment with other prophylactic or therapeutic agents. In accordance with the Society of Thoracic Surgeons guidelines on prophylaxis and management of POAF in general thoracic surgery, these data suggest that amiodarone is a safe agent for the management of POAF after lung resection. Careful monitoring in patients treated with amiodarone after pneumonectomy should be considered because development of acute lung toxicity can increase length of hospital stay, morbidity and mortality. Further studies may also be needed to identify the subset of pneumonectomy patients at risk of pulmonary toxicity after use of amiodarone.
[Mh] Termos MeSH primário: Amiodarona/uso terapêutico
Fibrilação Atrial/prevenção & controle
Pneumopatias/cirurgia
Pneumonectomia/efeitos adversos
Complicações Pós-Operatórias/prevenção & controle
[Mh] Termos MeSH secundário: Idoso
Antiarrítmicos/uso terapêutico
Fibrilação Atrial/etiologia
Seres Humanos
Complicações Pós-Operatórias/etiologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/icvts/ivx007


  8 / 7223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28471569
[Au] Autor:Wasserstrum Y; Raanani P; Kornowski R; Iakobishvili Z
[Ad] Endereço:Department of Cardiology, Rabin Medical Center (Beilinson Campus), Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
[Ti] Título:Concomitant Treatment with Ibrutinib and Amiodarone Causing Reversible Heart Failure Syndrome.
[So] Source:Isr Med Assoc J;18(7):433-434, 2016 Jul.
[Is] ISSN:1565-1088
[Cp] País de publicação:Israel
[La] Idioma:eng
[Mh] Termos MeSH primário: Amiodarona/efeitos adversos
Fibrilação Atrial/induzido quimicamente
Pirazóis/efeitos adversos
Pirimidinas/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Amiodarona/administração & dosagem
Inibidores do Citocromo P-450 CYP3A/administração & dosagem
Interações Medicamentosas
Insuficiência Cardíaca/induzido quimicamente
Seres Humanos
Masculino
Pirazóis/administração & dosagem
Pirimidinas/administração & dosagem
Síndrome
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytochrome P-450 CYP3A Inhibitors); 0 (PCI 32765); 0 (Pyrazoles); 0 (Pyrimidines); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE


  9 / 7223 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28904685
[Au] Autor:Affangla DA; Leye M; Simo AW; D'Almeida F; Sarr TY; Phiri A; Kane A
[Ad] Endereço:Hôpital Saint Jean de Dieu, Thiès, Sénégal.
[Ti] Título:[Poorly tolerated broad QRS complex tachycardia in a newborn].
[Ti] Título:Une tachycardie à QRS large mal tolérée chez un nourrisson..
[So] Source:Pan Afr Med J;27:157, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:fre
[Ab] Resumo:Poorly tolerated broad QRS complex tachycardia in a newborn poses problems with its diagnosis and emergency management. We report the case of a 35-day-old newborn with broad QRS complex tachycardia admitted because of cardiocirculatory distress. Doppler echocardiography showed morphologically normal heart. The patient received a loading dose of amiodarone but it didn't attenuate tachycardia. Normal sinus rhythm was restored after cardioversion through Lifeline semi-automatic external defibrillator. Maintenance therapy was based on oral amiodarone. The patient had normal sinus rhythm at 03 months of follow-up.
[Mh] Termos MeSH primário: Amiodarona/uso terapêutico
Antiarrítmicos/uso terapêutico
Cardioversão Elétrica/métodos
Taquicardia/diagnóstico
[Mh] Termos MeSH secundário: Terapia Combinada
Ecocardiografia Doppler
Eletrocardiografia
Feminino
Seguimentos
Seres Humanos
Recém-Nascido
Taquicardia/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.27.157.10364


  10 / 7223 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28865890
[Au] Autor:Darkner S; Goetze JP; Chen X; Henningsen K; Pehrson S; Svendsen JH
[Ad] Endereço:Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: stinedarkner@hotmail.com.
[Ti] Título:Natriuretic Propeptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT Trial).
[So] Source:Am J Cardiol;120(8):1309-1315, 2017 Oct 15.
[Is] ISSN:1879-1913
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Natriuretic peptides are established plasma markers of systolic heart failure, but their usefulness for the evaluation of atrial fibrillation (AF) is unknown. We examined mid-regional pro-atrial natriuretic peptide (MR-proANP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients undergoing ablation for AF. A subpopulation of 102 patients (median age 60 [52;65], 82% male) from the AMIO-CAT trial (Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study) undergoing ablation for paroxysmal (n = 55) or persistent (n = 47) AF was studied. MR-proANP and NT-proBNP were measured before ablation and at 1, 3, and 6 months' follow-up. Three-day Holter monitoring was performed before ablation, and 6 to 8 weeks and 6 months after ablation. Plasma MR-proANP and NT-proBNP concentrations were higher during AF than during sinus rhythm before ablation (188 pmol/L [131;260] vs 94 pmol/L [64;125], p <0.001; 78 pmol/L [43;121] vs 10.3 pmol/L [5.9;121], p <0.001) and at 1, 3, and 6 months' follow-up. Categories of AF burden on 3-day Holter monitoring (0%, 0% to 99%, and 99% to 100%) were associated with plasma concentrations of both MR-proANP (94 pmol/L [55;127] vs 117 pmol/L [88;185] vs 192 pmol/L [127;261], p <0.001) and NT-proBNP (10 pmol/L [5.9;22] vs 22 pmol/L [8.9;53] vs 81 pmol/L [45;116], p <0.001). In a multivariate regression analysis, however, there was no significant association between baseline propeptide concentrations and recurrence of AF at 6 months' follow-up. In conclusion, AF was associated with higher plasma concentrations of MR-proANP and NT-proBNP than sinus rhythm. Moreover, AF burden was associated with subsequent concentrations of both MR-proANP and NT-proBNP. The results suggest that natriuretic propeptide measurement reflects functional cardiac dysfunction during AF, and that AF burden should be included in biochemical assessment of left ventricular dysfunction.
[Mh] Termos MeSH primário: Amiodarona/administração & dosagem
Fibrilação Atrial/sangue
Ablação por Cateter/métodos
Peptídeos Natriuréticos/sangue
[Mh] Termos MeSH secundário: Administração Oral
Idoso
Antiarrítmicos/administração & dosagem
Fibrilação Atrial/terapia
Biomarcadores/sangue
Método Duplo-Cego
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Recidiva
Reprodutibilidade dos Testes
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); 0 (Biomarkers); 0 (Natriuretic Peptides); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170904
[St] Status:MEDLINE



página 1 de 723 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde